Lead Product(s): Tak-580
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Access Biotechnology
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing May 21, 2020
The company intends to use the funds to continue to expand development of its clinical-stage oncology treatment acquired through Takeda Pharmaceutical Company Limited.